No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Roquefort Therapeutics revealed on Monday that interim managing director Darrin Disley had acquired 5.0m ordinary shares in the London-listed material biotech company.
Disley, who joined Roquefort in September 2022, purchased the shares on Friday at an average price of 1.70p each, for a total value of 85,000.
As a result of the transaction, Disley now holds a beneficial interest in 7.02m ordinary Roquefort shares, representing approximately 4.46% of Roquefort's issued share capital.
As of 1530 GMT, Roquefort shares were up 1.29% at 1.92p.
Reporting by Iain Gilbert at Sharecast.com
Top Director Buys
Roquefort Therapeutics (ROQ)
Director name: Disley,Dr Darrin
Amount purchased: 5,000,000 @ 170.00p
Value: 85,000
Mobius Investment Trust (MMIT)
Director name: Dyer Bartlett ,Diana
Amount purchased: 21,469 @ 137.50p
Value: 29,519.88
Grainger (GRI)
Director name: Fraser,Simon
Amount purchased: 15,000 @ 183.00p
Value: 27,450.00
Paypoint (PAY)
Director name: Harding,Rob
Amount purchased: 1,924 @ 519.00p
Value: 9,985.56
Top Director Sells
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.